Shirin Hekmatirad

Dr. Shirin Hekmatirad


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2025 in Molecular & Cellular Toxicology
Verified
Journal Article
Closed access
PDF file
SBSaeed aghebat bekheir
Saeed aghebat bekheir
SHShirin Hekmatirad
Shirin Hekmatirad
NANasim Assar
Nasim Assar
MAMohammad Abdollahi
Mohammad Abdollahi

2 November 2025 in Journal of Research in Pharmacy
Verified
Journal Article
Closed access
KPKiarash Zohori Pour
Kiarash Zohori Pour
MFMarjan Fallah
Marjan Fallah
SHShirin Hekmatirad
Shirin Hekmatirad
Cisplatin-based regimens are indicated for the treatment of a broad spectrum of solid malignancies. Bladder cancer is among the solid malignancies in which cisplatin is used as the first-line treatment. Despite the high success rate of cisplatin therapy, a subset of patients experience poor prognosis and develop resistance to cisplatin. For this reason, there is still a need to find new drug targets to overcome cisplatin resistance and improve response in patients with bladder cancer. This study aimed to find a potential target to help restore bladder cancer sensitivity to cisplatin. First, two microarray datasets were analyzed to find the gene signatures related to cisplatin resistance. Akinase anchor protein 5 (AKAP5) gene was selected as a possible target in cisplatin resistance. To find a suitable AKAP5 inhibitor, a virtual screening of a FDA-approved library was performed and 5-methyltetrahydrofolate (5-MTHF) was selected for the subsequent investigation. Finally, the effect of AKAP inhibition on the cytotoxicity of cisplatin in 5637 cells was determined using the MTT assay. Molecular docking of the selected inhibitor against AKAP5 was performed to validate the virtual screening results and the docking scores were in line with the virtual screening results. Cotreatment with 5-MTHF significantly increased cytotoxicity in 5637 cells treated with 2.5 μM of cisplatin, compared to the groups not receiving 5-MTHF (P